Austrianova Singapore, a partner Of Pharmacyte Biotech Inc (OTCMKTS:PMCB), has completed the second and final run of the GMP manufacturing process that will be used for the production of Pharmacyte’s clinical trial product. The clinical trial product of Pharmacyte is ready for release testing. The information collected from release testing in both the manufacturing runs would be included in the IND (an investigational new drug application). It will be sent to the US FDA for supporting the planned clinical trial of Pharmacyte in patients suffering from inoperable and advanced pancreatic cancer.
Austrianova ships frozen syringes for lab testing
Austrianova has filled the genetically modified live cells into clinical trial syringes of Pharmacyte and frozen. It has shipped a frozen syringe sample to Europe for release testing in a third-party lab. The lab will test the safety of the final release product. Austrianova will then conduct the functionality test of the live encapsulated cells in its in-house.
Kenneth L. Waggoner, CEO of PharmaCyte, said the company is excited to complete the two production runs. It is now ready to progress towards submitting IND to the US FDA to begin the clinical trial in inoperable and advanced pancreatic cancer.
Changes the future of curing diseases
The technology of Pharmacyte expects to make a change in the way several hard to cure diseases are treated soon. The company would offer a new lease of life to LAPC (locally advanced, inoperable pancreatic cancer) patients by reducing the size of the tumors by inching closer in its upcoming phase 2b clinical trial. The surgeons can safely remove the small tumors through surgery later.
With these clinical trials, Pharmacyte addresses the unmet medical needs of patients by shrinking the tumors. In the second instance, the clinical trial helps to validate the safety and effectiveness of the Cell-in-Box in humans.
Kenneth said the company is planning to change the way hard to treat diseases that are cured in the future by validating its technology in a clinical trial. It is continually developing new cell lines, mainly genetically engineered cell lines, to cure several diseases. The validation of Cell-in-Box removes the boundaries to treat diseases.
Business intelligence from Akerna Corp (NASDAQ:KERN) Says Liquor Sales are Up 10% Year-over-Year
Post Views: 388 Liquor sales are up 10% year-over-year according to business intelligence from Akerna Corp (NASDAQ:KERN). Red wine took...
Pyxis Tankers Inc. (NASDAQ:PXS) Announce Q1 2020 Financial Results Amid COVID-19 Uncertainties
Post Views: 227 Pyxis tankers Inc. (NASDAQ:PXS) has announced its unaudited financial results for the quarter that ended March 31,...
Innovative Industrial Properties Inc (NYSE:IIPR) Enters Into a Lease Amendment Agreement with Green Leaf
Post Views: 249 With pot being legalized in many countries, the market is likely to get even bigger. As a...
Liberty Leaf Holdings Ltd (OTCMKTS:LIBFD) Takes Over Nova Mentis Biotech Corp And Add Synergies To Its Cannabis Assets In The Wellness And Health Sector
Post Views: 253 Liberty Leaf Holdings Ltd (OTCMKTS:LIBFD) gained access to the psilocybin by acquiring Nova Mentis Biotech Corp. The...
Aleafia Health Inc (OTCMKTS:ALEAF) Begins Cultivation At Its Entire Niagara Facility And Provides Consistent Supplies for Health: Settles Disputes With Aphria
Post Views: 358 Aleafia Health Inc (OTCMKTS:ALEAF) will commence cultivation operations at its whole Niagara facility. It obtained a license...
Pure Capital Calls For Shareholders Meeting of Therapix Biosciences Ltd (NASDAQ:TRPX): Demands For Dismissal Of Board Members
Post Views: 296 Pure Capital called for an emergency meeting of investors of Therapix Biosciences Ltd (NASDAQ:TRPX) to discuss actions...